Medtronic's tremor control therapy cleared by FDA:
This article was originally published in Clinica
Executive Summary
Medtronic has received clearance from the FDA to market its Activa implantable device for treating tremor in the US. The system is intended for control of unilateral essential tremor and tremor associated with Parkinson's disease. Medtronic, based in Minneapolis, Indiana, estimates that at least one million people in the US each year suffer from essential tremor and a further 500,000 people are affected by Parkinson's disease-related tremor.